2Seventy Bio Performance
| TSVTDelisted Stock | USD 5.00 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and 2Seventy Bio are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days 2Seventy Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, 2Seventy Bio is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
2Seventy |
2Seventy Bio Relative Risk vs. Return Landscape
If you would invest 500.00 in 2Seventy Bio on November 12, 2025 and sell it today you would earn a total of 0.00 from holding 2Seventy Bio or generate 0.0% return on investment over 90 days. 2Seventy Bio is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than 2Seventy, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
2Seventy Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of 2Seventy Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for 2Seventy Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| 2Seventy Bio is not yet fully synchronised with the market data | |
| 2Seventy Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 37.86 M. Net Loss for the year was (57.25 M) with loss before overhead, payroll, taxes, and interest of (13.24 M). | |
| 2Seventy Bio currently holds about 357.93 M in cash with (85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 82.0% of the company shares are owned by institutional investors |
2Seventy Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of 2Seventy Stock often depends not only on the future outlook of the current and potential 2Seventy Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. 2Seventy Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 52.2 M | |
| Cash And Short Term Investments | 174.8 M |
2Seventy Bio Fundamentals Growth
2Seventy Stock prices reflect investors' perceptions of the future prospects and financial health of 2Seventy Bio, and 2Seventy Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 2Seventy Stock performance.
| Return On Equity | -0.0194 | |||
| Return On Asset | -0.0749 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | (0.11) % | |||
| Current Valuation | 335.53 M | |||
| Shares Outstanding | 53.23 M | |||
| Price To Book | 1.24 X | |||
| Price To Sales | 5.50 X | |||
| Revenue | 37.86 M | |||
| EBITDA | (115.43 M) | |||
| Cash And Equivalents | 357.93 M | |||
| Cash Per Share | 9.45 X | |||
| Total Debt | 243.72 M | |||
| Debt To Equity | 0.73 % | |||
| Book Value Per Share | 4.08 X | |||
| Cash Flow From Operations | (85 M) | |||
| Earnings Per Share | (0.08) X | |||
| Total Asset | 479.51 M | |||
| Retained Earnings | (568.46 M) | |||
About 2Seventy Bio Performance
Assessing 2Seventy Bio's fundamental ratios provides investors with valuable insights into 2Seventy Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the 2Seventy Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2Seventy Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.Things to note about 2Seventy Bio performance evaluation
Checking the ongoing alerts about 2Seventy Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 2Seventy Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 2Seventy Bio is not yet fully synchronised with the market data | |
| 2Seventy Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 37.86 M. Net Loss for the year was (57.25 M) with loss before overhead, payroll, taxes, and interest of (13.24 M). | |
| 2Seventy Bio currently holds about 357.93 M in cash with (85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 82.0% of the company shares are owned by institutional investors |
- Analyzing 2Seventy Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 2Seventy Bio's stock is overvalued or undervalued compared to its peers.
- Examining 2Seventy Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 2Seventy Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of 2Seventy Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 2Seventy Bio's stock. These opinions can provide insight into 2Seventy Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in 2Seventy Stock
If you are still planning to invest in 2Seventy Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the 2Seventy Bio's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |